Luoxin Pharmaceuticals Group Stock (002793.SZ): The employee stock ownership plan for 2024 has been completed through non-trading transfer.

On December 2, 2023, Gelonghui reported that luoxin pharmaceuticals group stock (002793.SZ) announced that on December 2, 2024, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. The company repurchased securities account held 18,219,503 shares of its stocks, which were transferred on November 29, 2024, to the "Luoxin Pharmaceutical Group Co., Ltd. - 2024 Employee Stock Ownership Plan" specialized securities account through a non-trading transfer. The number of transferred shares accounted for 1.68% of the total share capital of the company, with a transfer price of 2.03 yuan/share.

Gelonghui FinanceDec 2 17:15

Express News | More than 10 listed companies disclosed agreement transfer plan announcements this week. The actual controller of chahua modern housewares intends to transfer 15.06% of the shares by agreement.

BreakingsNov 23 11:30

Express News | Luoxin pharmaceuticals group stock: Rebeprazole sodium enteric-coated tablets have obtained the pharmaceutical registration certificate.

BreakingsNov 21 15:44

Luoxin Pharmaceuticals Group Stock (002793.SZ) shareholders De Yi Chengdu, De Yi Hengjia, and De Yi Xinhua have terminated the matter of transferring shares to Yan Jinxia.

Luoxin pharmaceuticals group stock (002793.SZ) announcement, the company's shareholder De Yi Chengdu, De Yi Hengjia, De Yi Xinhua, and Yan Jinxia...

Zhitong FinanceNov 20 22:02

Express News | luoxin pharmaceuticals group stock: terminate the agreement to transfer 0.112 billion shares.

BreakingsNov 20 21:00

luoxin pharmaceuticals group stock (002793.SZ): The holding subsidiary plans to sell 100% equity of its wholly-owned subsidiary Lekang Pharmaceutical.

Grain Alliance News on November 18: Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that, in order to revitalize existing assets and optimize the company's resource allocation, the company's controlling subsidiary Shandong Luoxin plans to sell 100% equity of its wholly-owned subsidiary Lokang Pharmaceutical through the Linyi Equity Trading Center in an open listing manner. The listing price is determined to be 190 million yuan based on Lokang Pharmaceutical's latest net assets amount and considering the net asset increase after the debt-for-equity swaps in November 2024 (the final transaction price is subject to the open listing results). After this transaction is completed, Shandong Luoxin, the company's controlling subsidiary, will no longer hold equity in Lokang Pharmaceuticals, and Lokang Pharmaceuticals will not

Gelonghui FinanceNov 18 19:14